# Challenges in Cannabinoid HIV Clinical Trials: Enrollment and Stigma

> **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637)
> **Publisher:** CED Clinic (https://cedclinic.com)
> **Canonical URL:** https://cedclinic.com/cannabinoid-hiv-clinical-trials-enrollment-barriers/
> **Published:** 2026-04-23T23:01:23-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T15:58:59-04:00
> **Clinical Summary:** Explore challenges in cannabinoid HIV clinical trials, focusing on enrollment barriers and stigma despite cannabis legalization in Canada.

---

By **Dr. Benjamin Caplan, MD**  |  Board-Certified Family Physician, CMO at CED Clinic  |  Evidence Watch

Clinical Insight | CED Clinic

A Canadian pilot trial aimed to test oral cannabinoids in people living with HIV but managed to enroll only 10 of 205 individuals approached, with cannabis-related stigma as the most commonly cited reason for refusal. The study provides no efficacy data but offers critical lessons about why [cannabinoid research](https://cedclinic.com/cannabinoids-in-reward-processing-pain-perception/) in HIV populations remains extraordinarily difficult, even where cannabis is fully legal.

## Cannabis HIV Trial Reveals Major Recruitment Barriers, Even Where Cannabis Is Legal

A Canadian pilot randomized clinical trial (CTNPT 028) testing oral CBD and THC capsules in people with HIV on antiretroviral therapy enrolled only 10 of 26 planned participants from a pool of 205 approached individuals, with cannabis stigma and excessive visit burden as the dominant obstacles to participation.

CED Clinical Relevance
#72
High Relevance
This feasibility report provides actionable intelligence for designing future cannabinoid trials in HIV and underscores that legal access alone does not resolve research barriers.

[Cannabis Clinical Trials](https://cedclinic.com/cannabinoids-hormone-receptor-positive-breast-cancer/)
HIV Inflammation
Feasibility Research
CBD THC Oral Capsules
Cannabis Stigma

Why This Matters

People living with HIV on antiretroviral therapy often experience persistent low-grade inflammation that contributes to cardiovascular disease, liver disease, and accelerated aging. Cannabinoids have shown anti-inflammatory promise in preclinical models, but translating that promise into human evidence requires clinical trials that can actually enroll participants. This feasibility report from Montreal exposes a sobering reality: cannabis stigma remains a more formidable obstacle to [cannabinoid research](https://cedclinic.com/cannabinoids-in-reward-processing-pain-perception/) than the legal and regulatory frameworks that once defined it, raising urgent questions about how we design and communicate [cannabis research](https://cedclinic.com/pediatric-cannabis-certification-care-children/) to the very populations it aims to serve.

Study at a Glance

Study Type
Feasibility and process outcomes report for an open-label, randomized, two-arm pilot RCT

Population
Adults (≥18 years) with HIV, suppressed viral load (

---

### Verification & Medical Governance

- **Lead Clinical Author:** Benjamin Caplan, MD
- **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House).
- **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`).
- **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/).
- **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637).
- **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).